Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Effective Treatment Strategies for the Management of Diabetic Macular Edema

By: Nancy Holekamp, MD, moderator; Alexander M. Eaton, MD; Matthew Ohr, MD; Charles C. Wykoff, MD, PhD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

CONTENT SOURCE
This continuing medical education (CME) activity captures content from a roundtable discussion held on May 1, 2016, in Seattle, WA.

TARGET AUDIENCE
This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.

Expiration Date: Saturday, September 30, 2017
Release Date: September 2016

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss the advantages and disadvantages of anti-VEGF therapy for patients with DME
  • Recognize the clinical benefits of intravitreal steroid implant therapy, especially in patients that are refractory or have persistent DME
  • Discuss the treatment of DR in the setting of DME with steroids
  • Outline a patient-centric treatment protocol for the treatment of DME

Accreditation and Designation Statement

ACCREDITATION STATEMENT

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

Nancy Holekamp, MD, moderator
Pepose Vision Institute
St. Louis, Missouri

Alexander M. Eaton, MD
Retina Health Center
Fort Myers, Florida

Matthew Ohr, MD
Havener Eye Institute
Columbus, Ohio

Charles C. Wycoff, MD, PhD
Retina Consultants of Houston, Blanton Eye Institute
Houston, Texas

It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Nancy Holekamp, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board: Alimera Sciences; Allergan; Katalyst; Ophthotech Corporation; and Regeneron Pharmaceuticals. Grant/Research Support: Alimera Sciences; Allergan; Neurotech Pharmaceuticals; and Ophthotech Corporation. Stock Shareholder: Katylst.

Alexander M. Eaton, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Speaker’s Bureau: Alimera Sciences. Grant/Research Support: Acucela; Alcon; Alimera Sciences; Allergan; Apellis Pharmeceuticals; Genentech; Iconic Therapeutics; and Tyrogenex. Stock Shareholder: Alimera Sciences; Ophthotech Corporation; pSivida Corp; and Regeneron Pharmaceuticals.

Matthew Ohr, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Bayer Pharmaceuticals; Clearside Biomedical; DORC International; Genentech; ONL Therapeutics; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Merck & Co.; Ophthotech Corporation; Regeneron Pharmaceuticals; and Roche Pharma.

Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of: Consultant/Advisory Board/ Speaker’s Bureau: Alcon; Alimera Sciences; Allergan; Bayer Pharmaceuticals; Clearside Biomedical; DORC International; Genentech; ONL Therapeutics; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Acucela; Alcon; Allegro Ophthalmics LLC; Allergan; Ampio Pharmaceuticals; Apellis Pharmaceuticals; Clearside Biomedical; Genentech; Iconic Therapeutics; Ophthotech Corporation; pSivida Corp.; Regeneron Pharmaceuticals; Roche Pharma; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV; and XOMA Ltd.

Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Michelle Dalton, medical writer; and Melanie Lawler, PhD, reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Alimera Sciences.

Effective Treatment Strategies for the Management of Diabetic Macular Edema

Nancy Holekamp, MD, moderator; Alexander M. Eaton, MD; Matthew Ohr, MD; Charles C. Wykoff, MD, PhD

BackNext